Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg12/12 cls
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)Credit SuisseJason KantorDowngradeUnderperform (from neutral)-14%$6.34
Kantor lowered his target to $6 from $8, saying that metrics on the relaunch of Iclusig ponatinib

Read the full 332 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE